Role of tumor necrosis factor receptor expression in anterior chamber-associated immune deviation (ACAID) and corneal allograft survival

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 8, 2004, Pages 2674-2681

  Niederkorn, Jerry Y ^a   Mayhew, Elizabeth ^a   Mellon, Jessamee ^a   Hegde, Sushma ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADOPTIVE TRANSFER; ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORNEA TRANSPLANTATION; DELAYED HYPERSENSITIVITY; ENDOTHELIUM CELL; EPITHELIUM CELL; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; INCIDENCE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SUPPRESSOR CELL; SURVIVAL TIME;

ADOPTIVE TRANSFER; ANIMALS; ANNEXIN A5; ANTERIOR CHAMBER; ANTIGENS, CD; APOPTOSIS; ENDOTHELIUM, CORNEAL; EPITHELIUM, CORNEAL; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HYPERSENSITIVITY, DELAYED; ISOANTIGENS; KERATOPLASTY, PENETRATING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3242879783     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0144     Document Type: Article

References (37)

1. Niederkorn JY. The immune privilege of corneal grafts. J Leukoc Biol. 2003;74:167-171.
2. Group CCTSR. The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. Arch Ophthalmol. 1992;110:1392-1403.
3. Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Int Rev Immunol 2002;21:173-196.
4. Niederkorn JY. The immunology of corneal transplantation. Dev Ophthalmol. 1999;30:129-140.
5. Niederkorn JY. The immune privilege of corneal allografts. Transplantation. 1999;67:1503-1508.
6. Bora NS, Gobleman CL, Atkinson JP, Pepose JS, Kaplan HJ. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993;34:3579-3584.
7. Goslings WR, Prodeus AP, Streilein JW, Carroll MC, Jager MJ, Taylor AW. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Vis Sci. 1998;39:989-995.
8. Lass JH, Walter EI, Burris TE, et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci. 1990;31:1136-1148.
9. Sohn JH, Kaplan HJ, Suk HJ, Bora PS, Bora NS. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci. 2000;41:4195-4202.
10. Stuart PM, Griffith TS, Usui N, Pepose J, Yu X, Ferguson TA. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival. J Clin Invest. 1997;99:396-402.
11. Yamagami S, Kawashima H, Tsuru T, et al. Role of Fas-Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants. Transplantation. 1997;64:1107-1111.
12. Niederkorn JY. Anterior chamber-associated immune deviation. Chem Immunol. 1999;73:59-71.
13. Niederkorn TY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci. 1996;37:2700-2707.
14. Sonoda Y, Streilein JW. Impaired cell-mediated immunity in mice bearing healthy orthotopic corneal allografts. J Immunol. 1993;150:1727-1734.
15. Yamada J, Kurimoto I, Streilein JW. Role of CD4+ T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci. 1999;40:2614-2621.
16. Maumenee A. The influence of donor-recipient sensitization on corneal grafts. Am J Ophthalmol. 1951;34:142-152.
17. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci. 1991;32:2723-2728.
18. Ayliffe W, Alam Y, Bell EB, McLeod D, Hutchinson W. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol. 1992;76:602-606.
19. Hargrave SL, Mellon J, Niederkorn J. MHC matching improves corneal allograft survival in mice with Th2-immune bias. Transplant Proc. 2002;34:3413-3415.
20. Torres PF, De Vos AF, van der Gaag R, Martins B, Kijlstra A. Cytokine mRNA expression during experimental corneal allograft rejection. Exp Eye Res. 1996;63:453-461.
21. Larkin DF, Calder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Clin Exp Immunol. 1997;107:381-391.
22. Pleyer U, Milani JK, Ruckert D, Rieck P, Mondino BJ. Determinations of serum tumor necrosis factor alpha in corneal allografts. Ocul Immunol Inflamm. 1997;5:149-155.
23. Benson JL, Niederkorn JY. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber. Immunology. 1991;74:153-159.
24. D'Orazio TJ, Mayhew E, Niederkorn JY. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J Immunol. 2001;166:26-32.
25. Ksander BR, Sano Y, Streilein JW. Role of donor-specific cytotoxic T cells in rejection of corneal allografts in normal and high-risk eyes. Transpl Immunol. 1996;4:49-52.
26. He YG, Mellon J, Niederkorn JY. The effect of oral immunization on corneal allograft survival. Transplantation. 1996;61:920-926.
27. Elzey BD, Griffith TS, Herndon JM, Barreiro R, Tschopp J, Ferguson TA. Regulation of fas ligand-induced apoptosis by tnf. J Immunol. 2001;167:3049-3056.
28. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998;31:1-9.
29. Niederkom JY, Streilein JW. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases. J Immunol. 1982;128:2470-2474.
30. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.
31. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol. 1998;160:943-952.
32. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell. 1995;81:495-504.
33. Ferguson TA, Herndon JM, Dube P. The immune response and the eye: a role for TNF alpha in anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci. 1994;35:2643-2651.
34. Kawashima H, Yamagami S, Tsuru T, Gregerson DS. Anterior chamber inoculation of splenocytes without Fas/Fas-ligand interaction primes for a delayed-type hypersensitivity response rather than inducing anterior chamber-associated immune deviation. Eur J Immunol. 1997;27:2490-2494.
35. van der Poll T, Jansen J, Levi M, ten Cate H, ten Cate JW, van Deventer SJ. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J Exp Med. 1994;180:1985-1988.
36. Gao Y, Herndon JM, Zhang H, Griffith TS, Ferguson TA. Antiinflammatory effects of CD95 ligand (FasL)-induced apoptosis. J Exp Med. 1998;188:887-896.
37. D'Orazio TJ, Niederkorn JY. A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol. 1998;160:2089-2098.